Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns
Year: 2017
Type: article
Study design: Observational Study
Abstract: A glutamate-to-lysine variant (rs58542926-T) in transmembrane 6 superfamily member 2 ( TM6SF2 ) is associated with increased fatty liver disease and diabetes in conjunction with decreased cardiovascular disease risk. To identify mediators of the effects of TM6SF2 , we tested for associations between rs58542926-T and serum lipoprotein/metabolite measures in cross-sectional data from nondiabetic statin-naïve participants. We identified independent associations between rs58542926-T and apoB-100 particles (β = −0.057 g/l, P = 1.99 × 10 −14 ) and tyrosine levels (β = 0.0020 mmol/l, P = 1.10 × 10 −8 ), controlling for potential confounders, in 6,929 Finnish men. The association between rs58542926-T and apoB-100 was confirmed in an independent sample of 2,196 Finnish individuals from the FINRISK study (β replication = −0.029, P replication = 0.029). Secondary analyses demonstrated an rs58542926-T dose-dependent decrease in particle concentration, cholesterol, and triglyceride (TG) content for VLDL and LDL particles ( P < 0.001 for all). No significant associations between rs58542926-T and HDL measures were observed. TM6SF2 SNP rs58542926-T and tyrosine levels were associated with increased incident T2D risk in both METSIM and FINRISK. Decreased liver production/secretion of VLDL, decreased cholesterol and TGs in VLDL/LDL particles in serum, and increased tyrosine levels identify possible mechanisms by which rs58542926-T exerts its effects on increasing risk of fatty liver disease, decreasing cardiovascular disease, and increasing diabetes risk, respectively.
Source: Journal of Lipid Research
DOI: 10.1194/jlr.p076034
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,430
Funders: American Heart Association, Massachusetts General Hospital, Foundation for Cardiovascular Research, Helsingin Yliopisto, Wellcome Trust, Broad Institute, University of Bristol, Academy of Finland, Sydäntutkimussäätiö, Oulun Yliopisto, National Institutes of Health, Medical Research Council, National Human Genome Research Institute, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: G149876332, G2124545180, G235045266, Identifying Genes for Type 2 Diabetes: FUSION, Identification of genetic predictors of survival and pathophysiologic mechanisms in congenital heart disease patients, G4474400647, G5001017760, Human population based genetic studies to elucidate the biology of NAFLD, G6367303130, Identification and functional impact of NAFLD associated genetic variants, G9000277595, University of Michigan Training Program in Genomic Science, Michigan Diabetes Research Center (MDRC), Identifying Genes for Type 2 Diabetes: FUSION
OpenAlex ID: W2619692554
